Newronika Achieves CE Mark for Breakthrough αDBS® System in Deep Brain Therapy

Newronika's CE Mark Achievement for αDBS®

Newronika S.p.A., a leading medtech firm based in Milan, is setting a new standard in deep brain stimulation therapy with the recent acquisition of CE Mark certification for its innovative αDBS® (Adaptive Deep Brain Stimulation) system. This development signifies a monumental step towards enhancing patient care and paving the way for a future focused on personalized neuromodulation therapy.

A Groundbreaking Step in Medical Technology

The αDBS® system stands out in the realm of deep brain stimulation (DBS) technology. Unlike conventional DBS systems that deliver fixed stimulation, this adaptive system continuously monitors neural activity, allowing it to tailor stimulation according to real-time brain signals. This responsiveness not only promises improved therapeutic outcomes but also minimizes side effects, ensuring a less burdensome experience for both patients and healthcare providers.

The CE Mark certification now allows for the commercial use of αDBS® across the European Economic Area (EEA) and signifies its full integration with Newronika's proprietary cloud-based neural data platform, WebBioBank™. This integration is poised to revolutionize the way clinicians approach treatment for conditions such as Parkinson's disease, making the care process more efficient and adaptive to each patient's unique needs.

Understanding the Technology Behind αDBS®

The core of the αDBS® system is its patented Adaptive Therapy Stim Engine, which continuously senses local field potentials (LFPs). By gathering real-time data on brain activities, the system adjusts stimulation in response to the individual needs of each patient throughout the day. This innovation is based on over twenty years of rigorous research and development, establishing a comprehensive understanding of brain signal dynamics.

The αDBS® configuration includes an implantable pulse generator (IPG), a physician interface, and a patient remote control. This amalgamation allows seamless at-home data collection and fosters a connected care model, enabling clinicians to access longitudinal data that can guide ongoing therapy adjustments over time.

WebBioBank™: The Backbone of Personalized Therapy

At the heart of Newronika's approach is the WebBioBank™ platform, which serves as a crucial data infrastructure. WebBioBank™ collects and analyzes neural signals while integrating clinical data from various participating medical centers. This de-identified data repository grows more robust with every treatment, laying the groundwork for continuous improvements in personalized neuromodulation therapy.

Launched with support from Italy’s Ministry of Education, WebBioBank™ has undergone rigorous validation and peer-reviewed studies, contributing significantly to the understanding of neurophysiological dynamics and the mechanisms of DBS action. With patient privacy as a priority, the platform is engineered to protect sensitive information while facilitating groundbreaking advancements in neuromodulation.

Future Aspirations: FDA Approval and Beyond

In tandem with its achievements in Europe, Newronika has also secured an Investigational Device Exemption (IDE) from the United States FDA. This approval is instrumental for the ongoing ADVENT pivotal trial, which aims to support the FDA approval process for both conventional DBS and Newronika's αDBS® technology aimed specifically at Parkinson's disease treatment.

As the trial progresses, the αDBS® system remains investigational in the U.S., with stringent regulations governing its use. However, the ongoing research augurs well for the future of adaptive therapy in neurological care.

Conclusion

In essence, Newronika's endeavor with αDBS® is reshaping the landscape of deep brain stimulation therapy toward a more dynamic and patient-focused model. With the CE Mark secured, the promise of adaptive therapy now has the potential to change lives significantly, heralding a new era in the treatment of neurological diseases. For further information and updates on Newronika's innovative approaches, visit www.newronika.com and www.webbiobank.com.